📊 ACTU Key Takeaways
Is Actuate Therapeutics, Inc.. (ACTU) a Good Investment?
Actuate Therapeutics is a pre-revenue pharmaceutical company burning $5.0M operating cash flow per period with only $8.1M in cash reserves, implying critical runway constraints. While net losses improved 18.5% year-over-year, the absence of revenue generation combined with rapid cash depletion creates existential execution risk.
Actuate Therapeutics appears to be a pre-revenue biotech with no commercial income, persistent operating losses, and deeply negative returns on equity and assets, which makes current fundamental quality weak. The balance sheet is relatively clean with high cash balances, solid near-term liquidity, and no long-term debt, but cash burn of roughly $15.5M against $16.9M of cash suggests limited runway without meaningful clinical or financing progress.
Actuate Therapeutics, Inc.. Key Strengths (ACTU)
- Zero long-term debt eliminates financial leverage risk and provides refinancing flexibility
- Year-over-year loss improvement (18.5% net income, 67.5% EPS) demonstrates operational progress toward commercialization
- Adequate near-term liquidity with 1.80x current ratio provides 1-2 periods of operational funding
- Strong liquidity with a 2.74x current and quick ratio
- Cash represents most of the asset base, supporting near-term operations
- No meaningful long-term debt, limiting balance-sheet leverage risk
ACTU Stock Risks: Actuate Therapeutics, Inc.. Investment Risks
- No revenue and pre-revenue stage with unproven commercialization capability
- Critical cash runway of approximately 1.6 periods at $5.0M quarterly burn rate
- Negative free cash flow indicates unsustainable capital structure requiring dilutive financing
- Minimal asset base ($8.9M total assets) with limited collateral for future borrowing
- No revenue base, so the business is not yet self-sustaining
- Large recurring losses and negative operating cash flow indicate heavy cash burn
- Likely need for future capital raises if burn remains near current levels
Key Metrics to Watch
- Quarterly cash burn rate and updated cash runway estimates
- Clinical development milestones and regulatory pathway progress
- Equity financing activity and dilution impact on existing shareholders
- Quarterly operating cash burn relative to cash on hand
- Clinical and regulatory progress that could translate into revenue or partnership inflows
Actuate Therapeutics, Inc.. (ACTU) Financial Metrics & Key Ratios
💡 AI Analyst Insight
Actuate Therapeutics, Inc.. presents a mixed fundamental picture. Review the detailed metrics above to form your own investment thesis.
ACTU Profit Margin, ROE & Profitability Analysis
ACTU vs Healthcare Sector: How Actuate Therapeutics, Inc.. Compares
How Actuate Therapeutics, Inc.. compares to Healthcare sector averages
Sector benchmarks are approximate industry averages. Actual sector performance may vary.
Is Actuate Therapeutics, Inc.. Stock Overvalued? ACTU Valuation Analysis 2026
Based on fundamental analysis, Actuate Therapeutics, Inc.. has mixed fundamental signals relative to the Healthcare sector in 2026.
Note: This is a fundamental analysis based on SEC filings. For P/E ratio, price targets, and market-based valuation, consult financial data providers. This is not investment advice.
Actuate Therapeutics, Inc.. Balance Sheet: ACTU Debt, Cash & Liquidity
ACTU Revenue & Earnings Growth: 5-Year Financial Trend
5-Year Trend Summary: Actuate Therapeutics, Inc..'s revenue has remained relatively flat over the 5-year period, with a 0% decline. The most recent EPS of $-3.26 indicates the company is currently unprofitable.
ACTU Revenue Growth, EPS Growth & YoY Performance
Actuate Therapeutics, Inc.. Dividends, Buybacks & Capital Allocation
ACTU SEC Filings: Latest 10-K & 10-Q Analysis
Access official SEC EDGAR filings for Actuate Therapeutics, Inc.. (CIK: 0001652935)
📋 Recent SEC Filings
❓ Frequently Asked Questions about ACTU
What is the AI rating for ACTU?
Actuate Therapeutics, Inc.. (ACTU) has a Combined AI Grade of C from Claude (C) and ChatGPT (C) with 78% combined confidence, based on fundamental analysis of SEC EDGAR filings.
What are ACTU's key strengths?
Claude: Zero long-term debt eliminates financial leverage risk and provides refinancing flexibility. Year-over-year loss improvement (18.5% net income, 67.5% EPS) demonstrates operational progress toward commercialization. ChatGPT: Strong liquidity with a 2.74x current and quick ratio. Cash represents most of the asset base, supporting near-term operations.
What are the risks of investing in ACTU?
Claude: No revenue and pre-revenue stage with unproven commercialization capability. Critical cash runway of approximately 1.6 periods at $5.0M quarterly burn rate. ChatGPT: No revenue base, so the business is not yet self-sustaining. Large recurring losses and negative operating cash flow indicate heavy cash burn.
What is ACTU's revenue and growth?
Actuate Therapeutics, Inc.. reported revenue of N/A.
Does ACTU pay dividends?
Actuate Therapeutics, Inc.. does not currently pay dividends.
Where can I find ACTU SEC filings?
Official SEC filings for Actuate Therapeutics, Inc.. (CIK: 0001652935) including 10-K, 10-Q, and 8-K reports are available on SEC EDGAR.
What is ACTU's EPS?
Actuate Therapeutics, Inc.. has a diluted EPS of $-0.24.
How is the AI analysis conducted?
Two independent AI systems — Claude (Anthropic) and ChatGPT (OpenAI) — analyze SEC EDGAR filings including 10-K annual reports and 10-Q quarterly reports. Each AI evaluates financial health, profitability ratios, balance sheet strength, and growth metrics. The combined grade reflects both perspectives for balanced insights.
What is ACTU's fundamental grade?
Based on our AI fundamental analysis in June 2026, Actuate Therapeutics, Inc.. has a C grade with 78% confidence. Review the strengths and risks sections above for full context. This is not investment advice.
Is ACTU stock overvalued or undervalued?
Valuation metrics for ACTU: ROE of -148.7% (sector avg: 15%), net margin of N/A (sector avg: 12%). Compare these metrics with sector averages to assess valuation.
What is ACTU's AI grade for 2026?
Our dual AI analysis gives Actuate Therapeutics, Inc.. a combined C grade for 2026. Revenue is data pending, with profitability at or below sector average. Always conduct your own research.
What is ACTU's free cash flow?
Actuate Therapeutics, Inc..'s operating cash flow is $-5.0M, with capital expenditures of N/A.
How does ACTU compare to other Healthcare stocks?
Vs Healthcare sector averages: Net margin N/A (avg: 12%), ROE -148.7% (avg: 15%), current ratio 1.80 (avg: 2).